Product Information
PRAVASTATIN SODIUM 40 MG TAB is a generic product labeled by Cipla USA Inc., priced at $0.0828 per EA under NDC 69097079105. Its NADAC has been published 92 times since Jan 1, 2025.
FDA first approved this application on May 11, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Cipla USA Inc.NDC
69097079105
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PRAVASTATIN SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA077987FDA Approved
5/11/2007
TE Code
AB
On Market Since
6/1/2024
Pharmacological Classes
Price Statistics
The NADAC for PRAVASTATIN SODIUM 40 MG TAB has been published 92 times since Jan 1, 2025, and over the history we have for it it has risen 8.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0828 per EA |
|---|---|
| All-time high | $0.0906 (Sep 10, 2025) |
| All-time low | $0.0761 (Jan 1, 2025) |
| 52-week high | $0.0901 |
| 52-week low | $0.0828 |
| Median price | $0.0859 |
| Average price | $0.0856 |
| Largest weekly change | +9.1% (Feb 19, 2025) |
| Weeks tracked | 92 |
| Tracking since | Jan 1, 2025 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 9% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PRAVASTATIN SODIUM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
HMG-CoA Reductase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PRAVASTATIN SODIUM 40 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for PRAVASTATIN SODIUM 40 MG TAB, manufactured by Cipla USA Inc., is $0.0828 per EA (NDC 69097079105), effective Sep 30, 2026.
How has the price of PRAVASTATIN SODIUM 40 MG TAB changed over time?
Over the history we have for it, the NADAC for PRAVASTATIN SODIUM 40 MG TAB has risen 8.8%. It has been tracked across 92 weekly CMS publications since Jan 1, 2025.
What are the highest and lowest recorded NADAC prices for PRAVASTATIN SODIUM 40 MG TAB?
Since Jan 1, 2025, the NADAC for PRAVASTATIN SODIUM 40 MG TAB has ranged from a low of $0.0761 (Jan 1, 2025) to a high of $0.0906 (Sep 10, 2025), with a median of $0.0859 per EA.
Are there cheaper alternatives to PRAVASTATIN SODIUM 40 MG TAB?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PRAVASTATIN SODIUM 40 MG TAB, is $0.0752 per EA — about 9% below PRAVASTATIN SODIUM 40 MG TAB.
Who manufactures PRAVASTATIN SODIUM 40 MG TAB?
PRAVASTATIN SODIUM 40 MG TAB (NDC 69097079105) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.